Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
0.00%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
ENDRA Life Sciences Inc.
Market Cap
$7.76M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.92M
Net Profit Margin
328.67%
TTM Avg
-11931.69%
3Y Avg
-10159.65%
5Y Avg
-9780.14%
Market Cap
$7.92M
Net Profit Margin
0.00%
TTM Avg
-431.21%
3Y Avg
-828.00%
5Y Avg
-552.00%
Market Cap
$7.95M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.55M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.53M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$8.13M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$8.26M
Net Profit Margin
N/A
TTM Avg
-206582.99%
3Y Avg
-143015.53%
5Y Avg
-102538.66%
Market Cap
$7.25M
Net Profit Margin
-0.61%
TTM Avg
-82.77%
3Y Avg
-131.16%
5Y Avg
-372.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ENDRA Life Sciences Inc. (NDRA) | $7.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | 328.67% | -11931.69% | -10159.65% | -9780.14% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.92M | 0.00% | -431.21% | -828.00% | -552.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.95M | 0.00% | 0.00% | 0.00% | 0.00% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| GT Biopharma, Inc. (GTBP)vs › | $8.13M | 0.00% | 0.00% | 0.00% | 0.00% |
| HeartSciences Inc. (HSCS)vs › | $8.26M | N/A | -206582.99% | -143015.53% | -102538.66% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -0.61% | -82.77% | -131.16% | -372.00% |
| Longeveron Inc. (LGVN)vs › | $7.21M | -1977.59% | -1280.67% | -1780.71% | -1415.68% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | -45761.31% |
| 2017-12-31 | -33498.39% |
| 2017-09-30 | -316.69% |
| 2017-06-30 | -2478.35% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -133.22% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | -179.90% |
| 2015-09-30 | -165.90% |
| 2015-06-30 | -165.60% |
| 2015-03-31 | -136.01% |
